modifier of polycystic kidney disease 6

O

Leishmania major resistance QTL 1

O

Leishmania major resistance QTL 3

O

Leishmania major resistance QTL 4

O

immune response to AAV2 QTL 1

O

immune response to AAV2 QTL 2

O

immune response to Factor IX QTL 2

O

Tmc1 modifier 1

O

Tmc1 modifier 3

O

M16 feed intake QTL 5

O

M16 feed intake QTL 3

O

Mfi8q1

M16 feed intake QTL 1

O

Mfe5q2

M16 feed efficiency QTL 1

O

M16 glucose QTL 1

O

M16 leptin QTL 2

O

abdominal fat percentage 2

O

abdominal fat percentage 5

O

abdominal fat weight 2

O

abdominal fat weight 4

O

body weight 1

O

body weight 3

O

body weight 4

O

kidney weight 1

O

kidney weight 4

O

kidney weight 5

O

spleen weight 3

O

spleen weight 4

O

spleen weight 5

O

body weight, QTL 7

1 46.74 cM

O

bone marrow graft rejection 2

O

bleomycin-induced pulmonary fibrosis 4

15 47.79 cM

O

cystic fibrosis modifier QTL 1

1 76.73 cM

O

methotrextate efficacy 1

O

methotrextate efficacy 3

O

methotrexate efficacy 5

O

methotrextate efficacy 8

O

methotrextate efficacy 9

O

induction of brown adipocytes 7

4 45.71 cM

O

Rafar interacting locus

O

Idd21c

insulin dependent diabetes susceptibility 21.3

18 4.46 cM

O

non-HDL QTL 8

O

non-HDL QTL 9

O

HDL QTL 36

O

HDL QTL 37

O

HDL QTL 39

O

L2

skull development traits QTL 3

O

E7.1

skull development traits QTL 5

O

L9.1

skull development traits QTL 7

O

E17|L17

skull development traits QTL 10

O

modifier of hg 1

2 45.25 cM

O